Literature DB >> 2207449

Markedly increased serum erythropoietin levels following conditioning for allogeneic bone marrow transplantation.

M R Abedi1, L Bäckman, L Boström, B Lindbäck, O Ringdén.   

Abstract

Serum erythropoietin (EPO) levels were measured by radioimmunoassay in 36 patients undergoing allogeneic bone marrow transplantation (BMT). Serum EPO levels before conditioning treatment for BMT were generally higher than the levels obtained from healthy controls (49 +/- 17 (SEM) and 17 +/- 0.6, respectively). One day prior to BMT, after conditioning by chemotherapy with or without total body irradiation, the mean EPO level was markedly elevated (218 +/- 23 U/l, p less than 0.001) and reached to its highest level at 1 week post-BMT (269 +/- 40 U/l). Although, the EPO levels were significantly lower at 1 month (98 +/- 24 U/l, p less than 0.001), they were still elevated up to 3 months post-BMT, after which they gradually normalized. Patients given methotrexate and cyclosporine for prophylaxis against graft-versus-host disease (GVHD) had significantly lower EPO levels during the first 3 months post-BMT than patients transplanted with T cell-depleted marrow (p less than 0.05). Patients with post-transplant nephrotoxicity had lower, though not statistically significant, EPO levels than patients with normal renal function (p = 0.07). Acute GVHD and number of blood transfusions had no influence on serum EPO levels after BMT.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2207449

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  3 in total

Review 1.  Clinical use of rHuEPO in bone marrow transplantation.

Authors:  S Klaesson
Journal:  Med Oncol       Date:  1999-04       Impact factor: 3.064

Review 2.  Inadequate erythropoietin response to anemia: definition and clinical relevance.

Authors:  G Barosi
Journal:  Ann Hematol       Date:  1994-05       Impact factor: 3.673

3.  Early and late adverse renal effects after potentially nephrotoxic treatment for childhood cancer.

Authors:  Esmee Cm Kooijmans; Arend Bökenkamp; Nic S Tjahjadi; Jesse M Tettero; Eline van Dulmen-den Broeder; Helena Jh van der Pal; Margreet A Veening
Journal:  Cochrane Database Syst Rev       Date:  2019-03-11
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.